It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neutrophils provide first line of host defense against bacterial infections utilizing glycolysis for their effector functions. How glycolysis and its major byproduct lactate are triggered in bone marrow (BM) neutrophils and their contribution to neutrophil mobilization in acute inflammation is not clear. Here we report that bacterial lipopolysaccharides (LPS) or Salmonella Typhimurium triggers lactate release by increasing glycolysis, NADPH-oxidase-mediated reactive oxygen species and HIF-1α levels in BM neutrophils. Increased release of BM lactate preferentially promotes neutrophil mobilization by reducing endothelial VE-Cadherin expression, increasing BM vascular permeability via endothelial lactate-receptor GPR81 signaling. GPR81−/− mice mobilize reduced levels of neutrophils in response to LPS, unless rescued by VE-Cadherin disrupting antibodies. Lactate administration also induces release of the BM neutrophil mobilizers G-CSF, CXCL1 and CXCL2, indicating that this metabolite drives neutrophil mobilization via multiple pathways. Our study reveals a metabolic crosstalk between lactate-producing neutrophils and BM endothelium, which controls neutrophil mobilization under bacterial infection.
Lactate is a by-product of glycolysis that can function via its G protein receptor GPR81. Here the authors show that LPS or Salmonella infection enhances glycolytic metabolism in bone marrow neutrophils, resulting in lactate production, which increases endothelial barrier permeability and mobilization of these neutrophils by targeting endothelial GPR81.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Department of Immunology, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
2 Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
3 Department of Immunology, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563); Life science Core facilities, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
4 Department of Pharmacology, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany (GRID:grid.418032.c) (ISNI:0000 0004 0491 220X)
5 University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
6 University Hospital, University Duisburg-Essen, Institute for Experimental Immunology and Imaging, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445)
7 University of Haifa, Department of Human Biology, Haifa, Israel (GRID:grid.18098.38) (ISNI:0000 0004 1937 0562)